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EDITORIAL REVIEW
When is cortisol a mineralocorticoid?
Our purpose is to review certain recent advances in the
understanding of peripheral glucocorticoid metabolism as it
may impact on the kidney. Two classes of enzymes which may
affect the physiologic and pathophysiologic actions of glucocor-
ticoids on the kidney (1 1/3-hydroxysteroid dehydrogenase and
steroid 6j3-hydroxylase) will be discussed. Abnormalities in
both enzyme systems hold some promise as contributors to the
development of essential hypertension, at least in certain in-
stances. For this reason, a major portion of this review deals
with our current state of knowledge of the pathophysiology of
steroid-induced hypertension. We will not cover many other
potentially important aspects of adrenal and extra-adrenal cor-
ticosteroid metabolism relevant to the kidney. The reader is
referred to recent reviews of these topics: aldosterone metab-
olism [1], corticosteroid 18-hydroxylation [2], 19-oxygenation
and demethylation [3], and 20-hydroxylation [2]. 11 3-hydroxy-
steroid dehydrogenase (1 1/3-OHSD) converts glucocorticoids to
inactive I 1-keto metabolites, and thus regulates occupancy and
stimulation of the mineralocorticoid receptor, by cortisol in
humans, or by corticosterone in the rat. Steroid 6/3-hydroxylase
(613-OHase) produces derivatives which are potential alternate
agonists, such as 6/3-hydroxycortisol (613-OH-F) or 6f3-hydroxy-
corticosterone (6/3-OH-B), which may in turn regulate renal
Na metabolism by a unique receptor system. Thus, the query
"When is cortisol a mineralocorticoid?" will be discussed.
Peripheral glucocorticoid metabolism
The metabolic pathways of cortisol pertinent to this review
(1 1/3-hydroxysteroid dehydrogenation and 6f3-hydroxylation)
are shown in Figure 1. Following the release of cortisol from the
adrenals (or the exogenous administration of cortisol or corti-
sone) levels of active hormone are balanced with those of the
inactive metabolite cortisone, through the actions of 1113-
OHSD. This reversible enzyme has been detected immunohis-
tochemically in numerous peripheral tissues (see below) but is
found in large amounts in liver and kidney [4]. Plasma levels of
cortisone are generally one-tenth those of cortisol, but because
of the greater affinity of CBG for cortisol compared to corti-
sone, circulating free cortisol and cortisone levels are nearly
equal [5], and the subsequent metabolism of both compounds is
similar. For instance, the 4—5 double bond on the A-ring of both
cortisol and cortisone is reduced to form either the 513- or
Sa-dihydro derivatives, the former predominating under normal
physiologic conditions. Subsequent hydrogenation of the A-ring
3-ketone produces 5f3-tetrahydrocortisol (THF), 5a-tetrahydro-
cortisol (allo-THF) or 5/3- and 5a-tetrahydrocortisone (THE).
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These reduced metabolites then undergo further hydroxylation
and glucuronidation prior to excretion. Thus, in normal humans
the excretion of unconjugated and unmetabolized cortisol is
minimal (<5%), and the conjugated urinary products of cortisol
and cortisone metabolism are nearly equal [6]. However,
changes in the metabolism of cortisol and cortisone (described
below) may lead to conditions characterized by mineralocorti-
coid effects of cortisol.
Alternatively, cortisol (as well as corticosterone) may un-
dergo 6f3-hydroxylation prior to excretion in urine, primarily as
free metabolite [reviewed in 6 and 7]. Under normal circum-
stances, 6/3-hydroxylation accounts for approximately 1 to 3%
of cortisol metabolism, although the metabolite is the most
abundant free steroid in urine. However, the contribution of
6/3-OH-F to total cortisol metabolism may increase when cor-
tisol secretion increases, since steroid 6/3-hydroxylase enzyme
activity is induced by substrate [cf. 8, 9]. Although hepatic
steroid 6J3-OHase activity is well-known, it has become increas-
ingly apparent that significant renal 6/3-hydroxylation occurs in
humans and other animals [9—14]. Plasma cortisol is 100-fold
that of 6/3-OH-F, and yet urinary excretion of free 6/3-OH-F is
5 to 10 times greater than free cortisol in humans [10], consis-
tent with substantial renal 6/3-OH-F production. In fact, the
urinary concentration of 6/3-OH-F is extremely high (0.5 to 5.0
X 106M) in normals, essential hypertensives and Cushing's
syndrome [our unpublished studies and published reports, cf.
10], a fact which could have important implications for pro-
posed pathophysiologic mechanisms of 6(3-OH-F in hyperten-
sion.
The mineralocorticoid-glucocorticoid hypothesis
Steroid hormones produced and secreted by the adrenal
cortex (as well as their synthetic steroid analogues) set into play
numerous and diverse physiologic and biochemical events by
their actions on target or effector cells. Steroid effects were first
categorized as either glucocorticoid, mineralocorticoid, andro-
genic, estrogenic or progestational, because the various effects
within a category could not be separated when comparing
activities of steroid analogues of varying potency. In other
words, "a specific mineralocorticoid, in a given animal, will
exert as potent an effect on sodium and potassium exchanges in
the sweat gland as in the kidney tubule or salivary gland.
Likewise, the relative capacity of a given glucocorticoid to be
antiinfiammatory, to be diabetogenic, to lower eosinophiles, or
to elevate the glomerular filtration rate in the same animal are
all approximately equal" [16]. The categories accurately pre-
dicted the presence of various steroid receptors [16], including
two classes of renal corticosteroid cytosolic and nuclear binding
sites designated mineralocorticoid and glucocorticoid receptors
(or Type I and Type II receptors, respectively). Type I and
Type II receptors have been demonstrated in human kidney [17,
1297
CH2OH "CHOH CI-120H
o
HO
OH
,.
—
coIl
Fig. i. Mewbolic pathiuv. ofcortisol mediated by either Ilfi-hydroxysteroid dehydrogenase or op-hydroxy/a.ve
HO
OH
6-fiOH-F
11j3-OHSD
- OH
0'
CORTISONE (E)
- OH
L613-OHase I( .,
5-reductase
CH2OH
OH
513-DHF
4,
HO
HO -cE?
OH
5j3-THF (THF)
4,
CORTISOL (F)
'N_5reductase
CH2OH
OH
5cz-DHF
4, CH2OH
OH
HO -
HO
CH2OH
0
- OH
H
5u-THF (aIIo-THF)
H
4,
CORTOLS ALLO-CORTOLS CORTOLONES
THE
4,
1298 Clore et a!: When is cortisol a mineralocorticoid?
Table 1. Renal effects of cortisol: Current concept of receptor
mediation, mineralocorticoid (Type I) and glucocorticoid (Type II)
Transient kaliuresis Type II
Transient natriuresis Type II
Sustained urinary Na* retention Type I
Sustained kaliuresis Type I
Increase proton excretion Type I
Increase ammoniagenesis Type I and/or II
Transient increased glomerular Type II
filtration rate
Increased diluting capacity Type II
a Human studies are based primarily on comparison of effects of
various corticosteroids and synthetic analogs, within the functional
categories of glucocorticoids and mineralocorticoids [16, 19—22]. In
certain cases, the effects of the mineralocorticoid receptor antagonist
spironolactone on steroid action was assessed.
18]. Subsequently, all effects of glucocorticoids and mineralo-
corticoids have been considered to be mediated by the Type I
and/or Type II receptor [19].
Table 1 outlines the current view of the receptor mediating
each effect of cortisol [16, 19—221. The acute kaliuresis and
associated natriuresis and GFR increase are considered glu-
cocorticoid effects [20, 23—25], based on studies using synthetic
analogues of cortisol. The Na retaining effect of cortisol, more
clearly demonstrable after the first 12 hours of administration
[24], is considered a mineralocorticoid action [221, However,
the role of Type I and Type II receptors in Na retention
induced by cortisol in humans has not been adequately ad-
dressed [261.
The Type I receptor antagonist spironolactone has been and
continues to be useful for in vivo as well as in vitro studies of
the functional role of the mineralocorticoid receptor. The
recently developed Type II receptor antagonist RU 38486
(RU486), which has a high affinity for Type II receptors and a
very low affinity for rat renal Type I receptors [27], offers an
opportunity to assess the role of Type II receptor activation in
the renal effects of corticosteroids. The concept that all actions
of mineralocorticoids and glucocorticoids can be explained by
Type I and Type II receptor occupancy, followed by activation
of nuclear mechanisms by the classic steroid receptor pathway
in target cells, has served the scientific community well. The
corollary that receptor affinity dictates receptor occupancy has,
however, now been challenged in the case of the modulation of
glucocorticoid occupancy of Type I receptor by target cell
metabolism (ll3-dehydrogenation) of the agonist. Also, studies
in our own lab (see below) raise the possibility that more than
two receptors mediate the effects of glucocorticoids.
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Contemporary molecular biologic techniques applied to ste-
roid receptors have revolutionized our understanding of mech-
anisms of steroid action and offer tremendous potential for
advances in understanding the role of steroidal regulation of
kidney function in health and in disease. O'Malley et al have
provided one of the many reviews of our current knowledge in
this area [28], but only certain aspects of these studies will be
discussed. The pioneering work of Evans and coworkers and
many other laboratories led to the concept that steroid receptor
proteins are members of a superfamily of transcriptional regu-
latory proteins which share a carboxyterminal ligand binding
domain, a DNA binding domain and an aminoterminal immu-
nogenic domain [29]. The latter domain is particularly variable
in size among the members of this family. The relative degree of
homology in the highly conserved DNA binding (zinc finger)
region allows two subsets of these receptors to be recognized,
that is: (1) the corticosteroid, progesterone, and androgen
receptor subfamily, and (2) the estrogen, vitamin D, thyroid and
retinoic acid subfamily [28, 30]. After the receptors have been
activated by ligand binding, the zinc finger region of the
proteins recognizes palindromic sequences in the regulatory
regions of target genes. As a rule, the activated receptors bind
as dimers to these enhancer hormone regulatory elements
(HREs) on the target genes and alter transcription regulation of
these specific genes. The high homology in the DNA binding
domain of receptors has, in turn, allowed homology cloning of
other receptors from genetic material (such as genomic and
eDNA libraries) using the base sequences of the DNA binding
domain of known receptors as probes to detect other receptors
which hybridize at low but not high stringency. Some of the
newly discovered members of the steroid receptor superfamily
have no known ligands and are called orphan receptors [28].
Pertinent to this review, Evans et al cloned and sequenced
the glucocorticoid receptor [31], and then used the homology
cloning technique and a fragment of the cDNA for the Type II
receptor containing the DNA binding domain to clone and
sequence the very closely homologous Type I receptor [32].
Subsequent studies have shown the cloned receptors to be
identical to the native Type I and Type II receptor in structure
and function, the latter based upon the ability of the activated
receptor to bind to the HRE.
Surprisingly, dexamethasone, which has very low affinity for
the Type I receptor, activated transcription of the reporter gene
when either Type I or Type II cDNAs were cotransfected into
cells containing a reporter gene regulated by glucocorticoid
HRE's. Aldosterone (a glucocorticoid at high concentration)
did not activate the reporter when the Type II receptor was
coexpressed, but did so only when cotransfected with the Type
I cDNA [32]. Such paradoxical observations between transfec-
tion studies and our experiences in vivo and in whole cells
highlight the complexity of receptor mediated events and offer
clues, and thus challenges, toward a deeper understanding of
these events [33].
Mineralocorticoid and glucocorticoid hypertension
Steroid-induced blood pressure elevation in humans also can
be categorized as mineralocorticoid or glucocorticoid. Since we
are discussing the role of steroid metabolism in hypertension,
these two forms of hypertension will be considered in some
detail. The distinction between the two types of steroid induced
Table 2. Characteristics of corticosteroid induced hypertension in
humans
Mineralocorticoid hypertension Glucorticoid hypertension
Urinary Na retention Urinary Na excretion may be
increased or decreased
Dependent on Na intake Modified by but not dependent
on Na intake
Increased total body Na No change in total body Na
(Cushing's disease)
Increased extra-cellular fluid and Increased extracellular fluid and
plasma volume plasma volume (acute studies)
Hypokalemia and decreased total Little or no change in serum
body K K
Low plasma renin concentration Increased renin substrate but
variable plasma renin
concentration
Inhibited by Type I receptor Inhibited by Type II antagonists
antagonists
hypertension was first clearly described by Knowlton et al
[34—36]. These investigators found that cortisone-induced hy-
pertension was Na intake independent whereas deoxycorti-
costerone (DOC)-induced hypertension was Na intake depen-
dent. Both DOC (a mineralocorticoid) and corticosterone (the
major glucocorticoid in the rat) produced an increase in extra-
cellular fluid volume (ECFV) and plasma volume (PV) associ-
ated with hypertension in intact rat, although by different
mechanisms [37]. DOC administration expanded ECFV by
decreasing urinary and fecal Na excretion, whereas, corticos-
terone did so by shifting Na from the intracellular compart-
ment to the extracellular compartments. As a result, corticos-
terone produced a net Na loss over the five-day administration
period by increasing urinary Na excretion [37], so that only a
portion (albeit significant) of the Na lost from the intracellular
compartment actually remained in the ECF compartment.
These workers reasoned that corticosterone actually caused
renal conservation of Na to maintain the ECFV and PV
expansion. The decrease in urinary Na concentration and
decreased fractional excretion (GFR was increased) induced by
corticosterone was presented as evidence of such an alteration
in renal Na handling. They concluded that the final common
denominator in the pathogenesis of the two kinds of steroid
hypertension was expansion of the extracellular compartments,
associated with a renal defect in Na excretion. These two
pathophysiologic alterations were consistent with the hypothe-
sis of Guyton et al emphasizing the dominant role of renal
conservation of Na in regulation of blood pressure (BP) and in
hypertension [38].
In Table 2, those characteristics which seem most consis-
tently to be found in these two kinds of hypertension in humans
are listed. With respect to mineralocorticoid hypertension,
early studies [39, 40] demonstrated that a large daily dosage of
DOC or aldosterone produced an initial urinary Na retention
followed by an increase in urinary Na to approximate Na
intake in five to ten days, that is, an escape from the Na
retaining effects of the mineralocorticoid. Thereafter, continued
aldosterone administration produced a gradual increase in BP
[401. Based upon studies examining the effects of (1) a large
dose of 9cx-fiudrohydrocortisone (0.8 mg/day) [41], and (2) the
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of extracellular fluid volume — increase in cardiac output —*
increase in total peripheral resistance —* increased and sus-
tained arterial hypertension — excretion of salt and water. The
increased excretion of Na and water after two to three weeks
of continued mineralocorticoid excess is of interest. There is an
equal and parallel decrease in Na space (ECFV) to about 60%
of its maximum (Fig. 2B), associated with an almost complete
return of PV to normal (Fig. 2C) during the time that peripheral
resistance increases. Thus, in chronic aldosterone excess (pri-
mary aldosteronism) Na space is increased and PV is normal.
The difference in time-course and magnitude of change in
ECFV and PV may be of importance in explaining the contin-
____________________________________
ued increase in BP and peripheral resistance, but its significance
is unclear. According to the hypothesis of Guyton [38], in-
creased cardiac output and increased peripheral tissue flow
leads to tissue auto-regulation of flow, that is, a locally medi-
ated increase in peripheral resistance, and these changes alone
are sufficient to explain the development of sustained hyperten-
sion. However, we must also point out that the central nervous
system and subsequent alteration in peripheral vascular tone
and direct and indirect alteration in vascular reactivity may play
a role in the development of mineralocorticoid or volume
dependent hypertension [44, 45]; also, reference 46 is a recent
review containing provocative data on CNS effects of corticos-
teroids on BP.
There are no longitudinal studies of these same parameters in
glucocorticoid hypertension in humans which are of similar
length to the studies in mineralocorticoid hypertension (Fig. 2),
that is, of several weeks duration. However, studies examining
the acute effects of glucocorticoids have demonstrated changes
in blood pressure independent of the Type I receptor. Grunfeld
and coworkers [47] found that RU-26988, a high affinity glu-
cocorticoid agonist with little or no affinity for the Type I
receptor, induced hypertension in the rat. This BP elevation
was prevented by two glucocorticoid antagonists (RU-486 and
progesterone) and was not inhibited by a high affinity mineralo-
corticoid receptor antagonist (RU-283 18). The most detailed
studies of acute glucocorticoid alteration in urinary Na excre-
tion, BP and fluid volume in humans are from the laboratories of
Whitworth, Fraser and Scoggins et al [48—511. In these studies
high dose cortisol and ACTH consistently produce an increase
in systolic blood pressure (SBP) in two to three days. Presum-
ably this SBP increase is a harbinger of sustained glucocorticoid
diastolic hypertension. It is modified by dietary Na manipula-
tion but is Na independent [51]. However, there is an associ-
ated Na retention, an initial increase in ECFV and PV and an
increase in cardiac output. Na restriction prevents the ECFV
increase but not the acute increase in PV, suggesting a com-
partment shift as described in the rat [37].
We have extended the observations of Whitworth, Fraser,
Scoggins and associates by examining the effects of high
dosages (stress levels) of ACTH and cortisol with and without
spironolactone (Type I receptor antagonist) and RU486 (Type II
receptor antagonist) administered for five days to normal young
males on a constant daily diet. Our goal was to determine to
what degree the acute effects of cortisol on electrolyte excretion
and systolic BP (SBP) elevation could be attributed to the
mineralocorticoid and glucocorticoid receptors, respectively
[52]. RU486 failed to inhibit the urinary Na retention and SBP
I I
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Fig. 2. Idealized time-course of changes in blood pressure, fluid com-
partments and hemodynamics secondary to mineralocorticoid excess in
humans. Values are expressed in relative units with a zero time value of
1.0 and represent approximations from two studies: Subjects with
primary aldosteronism, studied by Wenting, Schalekamp and cowork-
ers, who were taken off spironolactone therapy and studied as the
hypertension redeveloped [42]; Normal subjects administered high-
dose 9a-fluorohydrocortisone (0.8 mg/day) as studied by Distler and
Mainz [41].
discontinuation of spironolactone therapy in patients with pri-
mary aldosteronism [421, we have depicted the natural history
of mineralocorticoid hypertension in Figure 2. As discussed by
Distler and Mainz [41], this sequence of events follows the
course predicted by Guyton [38] and Ledingham [43]: Miner-
alocorticoid excess — retention of salt and water —+ expansion
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Table 3. Effects of mineralocorticoid (Type I) and glucocorticoid
(Type II) receptor antagonists on actions of high dosage
corticosteroids in humans 52, 53]
Agonist cortisol
(240 mglday)
Antagonist
Spironolactone Ru486
Antinatriuresis Not inhibited Not inhibited
SBP increase Not inhibited Not inhibited
Decrease plasma K Inhibited Not inhibited
Transient kaliuresis Not inhibited Inhibited
Increased ammonia Not inhibited Inhibited
excretion
Increase fasting blood sugar Not inhibited Inhibited
and plasma insulin
9a-fludrohydrocortisone
(3.0 mg/day)
Inhibited NDAntinatriuresis
SBP unchanged No effect ND
Decreased plasma K Inhibited ND
Transient kaliuresis Accentuated ND
Abbreviation is: ND, not done.
increase induced by high dose cortisol. Similarly, spironolac-
tone failed to inhibit either parameter in subjects given high
dose ACTH or cortisol. These studies suggested that neither the
acute hypertensinogenic nor the antinatriuretic effect of stress
level cortisol was mediated by the Type I and Type II receptor.
Proof of adequate receptor blockade by the antagonists is
essential to the conclusion that cortisol's increase in SBP and
Na retention was mediated by a mechanism other than via
Type I or Type II receptors. Therefore, these experiments in
humans were extended to encompass a comparison of the
urinary Na retention and SBP change produced by high
dosage of cortisol (240 mg/day) and the mineralocorticoid
9a-fludrohydrocortisone (9aFF, 3.0 mg/day), with and without
spironolactone administration [53]. High dose 9a-FF adminis-
tration produced a twofold greater five-day cumulative urinary
Na retention compared to cortisol's effects. However, the
same dose of spironolactone completely inhibited the Na
retention produced by the mineralocorticoid but again did not
alter the Na retention (or the SBP increase) induced by
cortisol. Thus, spironolactone was administered at a Type I
receptor "blocking" dose in the cortisol studies, but the mm-
eralocorticoid-like effects of the glucocorticoid were not pre-
vented [53]. Other evidence of adequate Type I receptor
blockade by spironolactone and Type II receptor blockade by
RU486 in these human studies [52, 53] is summarized in Table
3. Thus, it is quite possible that stress levels of cortisol induce
increases in BP and urinary Na retention by a third receptor
which is neither Type I or Type II.
The Na space (ECFV) is generally normal in patients with
Cushings disease [541. This is in contrast to findings in states of
chronic mineralocorticoid excess, or in the acute studies of
cortisol excess described above. Likewise, evidence of ex-
panded PV is not always present in rat models of glucocorticoid
hypertension [47, 55, 56]. This variation is generally thought to
be due to the variable degree to which the steroid analogue used
has mineralocorticoid (Na retaining) or glucocorticoid (natri-
uretic) effects, although this correlation has not been well
defined, Also, the contribution of mineralocorticoid excess to
the BP and electrolyte disturbance in Cushings disease has not
been clarified. However, in adrenal tumors and in ectopic
ACTH syndrome mineralocorticoid excess-effects probably oc-
cur, at least in part, secondary to elevated corticosterone and
DOC [57]. In contrast, several cases of Cushings disease have
been treated with RU486 and the BP was found to decrease
slowly to normal as did the metabolic sequelae of cortisol
excess [581. It is not known to what degree the BP elevation of
Cushing's syndrome is dependent on the metabolic conse-
quences of long standing glucocorticoid excess, such as obesity
and insulin resistance, as opposed to the hypertensinogenic
effects noted in acute studies, the latter not inhibited by RU486
[52].
Inconsistency in studies of glucocorticoid hypertension exists
in several areas. First, there are species differences in hyper-
tensinogenic responses to various analogues. For instance,
dexamethasone is very hypertensinogenic in rats [561, but not in
dogs or sheep [59]. 9a-FF is a potent mineralocorticoid in
humans which produces glucocorticoid hypertension in rats and
hypertension in sheep at dosages which are not associated with
either glucocorticoid or mineralocorticoid effects [60]. This
latter finding in sheep and other data have prompted Whitworth
and coworkers to postulate a third "hypertensinogenic recep-
tor" in sheep and to speculate about the role of such a receptor
in mediating the hypertension induced in humans by ACTH and
cortisol [59, 60]. A second area of confusion is the role of the
renin-angiotensin system in glucocorticoid hypertension [60—
621. The plasma renin activity (PRA) is always markedly
decreased in mineralocorticoid hypertension. Plasma renin sub-
strate is always increased in glucocorticoid hypertension but
the effects of glucocorticoids on PRA are variable (possibly due
to the variable degree of Na retention in various model
systems). Similarly, the response of blood pressure to angio-
tensin converting enzyme inhibitors and to saralasin adminis-
tration is variable in states of glucocorticoid excess. There is
general agreement that the renin-angiotensin system plays, at
most, only a modest role in glucocorticoid hypertension [60—
62]. Numerous publications describe investigations into direct
and indirect effects of glucocorticoids on vascular reactivity, on
renal hemodynamics, the renin-angiotensin system, prostaglan-
dins, the kallikrein system, secretion of other hormones such as
atrial natriuretic peptide and tissue changes in Nat, K,
ATPase. The reader is referred to recent reviews on the subject,
dealing particularly with glucocorticoid hypertension [60—62].
The rapid development of the techniques of molecular biology
and their application to renal problems should aid clarification
of some of these mechanisms of steroid dependent hyperten-
sion.
Recent investigations of glucocorticoid-remediable aldoste-
ronism (GRA) have clarified the pathophysiology of this rare
inherited syndrome. The hypokalemia, hyperaldosteronism and
suppressed plasma renin activity with mineralocorticoid hyper-
tension in this autosomal-dominant disease are reversed by
small doses of dexamethasone [63, 64]. Dexamethasone is
efficacious because it suppresses ACTH. Aldosterone synthesis
is under the control of ACTH and not the renin-angiotensin
system in GRA. Ulick and coworkers have shown increased
production of cortisol metabolites 18-hydroxy- and 18-oxocorti-
sol which are analogues to the precursor of aldosterone (18-
hydroxycorticosterone) and to aldosterone itself, respectively
[65, 66]. In a striking demonstration of the power of techniques
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of molecular genetics, Lifton and coworkers have recently
demonstrated fusion of the 5' regulatory region of the adrenal
enzyme 1 1/3-hydroxylase gene to the coding sequences for the
aldosterone synthase gene [67]. They proposed that this gene
product, a chimeric enzyme, would be aberrantly expressed in
adrenal fasciculata, where both cortisol and corticosterone are
produced, because of the 1 1/3-hydroxylase regulatory se-
quences. This would result in production of 18-oxocortisol,
l8-hydroxycortisol and aldosterone from cortisol and corticos-
terone in the zona fasciculata. Regulatory sequences of 11/3-
hydroxylase are under ACTH control. Therefore, glucocorti-
colds which suppress ACTH production of these three steroids
would suppress and eliminate the hypertension in GRA [67].
Dluhy and these same workers used increased urinary C-18
oxidation products as a marker for GRA in a study of a large
kindred [68]. All subjects who expressed the phenotype and
were over age 20 were hypertensive and generally were hy-
poreninemic. A surprising observation was that the quantity of
a urinary aldosterone metabolite and plasma aldosterone were
only modestly increased compared to normotensive kin not
demonstrating the phenotype. This may explain why all were
normokalemic, although it is noteworthy that several subjects
with GRA developed severe hypokalemia on hydrochiorothia-
zide therapy. Because most other reported cases were hy-
pokalemic, and this electrolyte finding was used as a screening
parameter in earlier cases, the authors suspect that many cases
of GRA may have been missed. The less than impressive degree
of aldosteronism and hypokalemia raise the possibility that the
increased cortisol C-18 oxidation metabolite production could
contribute to the hypertension, at least in part, by a mechanism
other than through Type I receptor mediation. Indeed, we have
shown that high dose ACTH-induced increase in SBP and
urinary Na retention is not inhibited by spironolactone (J.
Clore and C. Watlington, unpublished data). Yet in our studies,
the two cortisol C-18 metabolites were markedly increased
throughout the five-day administration of ACTH [69]. Although
we have speculated that 6/3-OH-cortisol may be the agonist for
the SBP increase and the Na retention mediated by a receptor
other than the mineralocorticoid receptor [52, 53], it is certainly
possible that in this case the agonists are the cortisol metabo-
lites. Whatever the pathophysiology, these findings mandate a
search for GRA among the essential hypertensive population.
To summarize, the acute and chronic effects of glucocorti-
coids show some similarities to mineralocorticoid effects in
terms of alteration of electrolyte metabolism, volume spaces
and hemodynamics. However, glucocorticoid and mineralocor-
ticoid hypertension are clearly two distinct entities and differ
according to Na dependence, Na space, receptor mediation,
effects on renin-angiotensin system and probably in effects on
K metabolism (Table 2). Our human studies raise the possi-
bility that glucocorticoid hypertension may be mediated by a
receptor other than the Type I or Type II receptor [52, 531.
11/3-hydroxysteroid dehydrogenase (1 1j3.OHSD)
In 1977, Ulick and colleagues identified a three-year old Zuni
Indian child who presented at nine months of age with spirono-
lactone-sensitive hypertension and hypokalemia, suggestive of
mineralocorticoid excess [70]. Extensive evaluation of this
subject demonstrated diminished plasma renin activity and
urinary aldosterone as well as subnormal urinary 17-hydroxy-
steroids and 17-ketosteroids. Provision of hydrocortisone or
ACTH resulted in increases in blood pressure which were
modified by but not dependent upon Na intake. Subsequent
studies [71] which examined cortisol metabolism with tracer
techniques, in this and an additional child, identified marked
increases in urinary free cortisol, 5a-dihydrocortisol and tet-
rahydrocortisol and decreased excretion of tetrahydrocortisone
(low THE:THF ratio) before and after exogenous administra-
tion of hydrocortisone. The conversion of cortisol to cortisone
as measured by the detritiation of 11 c-[3H]cortisol was unde-
tectable while the reverse reaction was not affected. Thus, the
authors concluded that a diminished rate of 1 1/3-OHSD conver-
sion of cortisol to cortisone (as well as an increase in 5a
reduction) might account for the apparent mineralocorticoid
excess (AME) observed in these and additional patients [71].
Edwards et a!, in describing the first adult with this syndrome,
proposed that the deficiency of 1 l/3-OHSD in kidney (rather
than liver) might be the key abnormality [72]. They suggested
that reduction of 11/3-hydroxylation might allow access of
cortisol to the Type I receptor at physiologic ECF concentra-
tion of cortisol. Monder eta! have been leaders in the evolution
of our current concepts of the pathophysiology of 1 l/3-OHSD
deficiency. Studies demonstrating that cortisol, normally
present in the circulation in concentrations 100-fold greater than
those of aldosterone, could bind to the Type I receptor with a
similar affinity to the presumed selective agonist aldosterone
[73] strongly supported the proposal of Edwards et al [72]. In
addition, these findings suggested that Type I receptor selectiv-
ity might be mediated by the prevention of cortisol's illicit
occupation of this receptor by 1 1/3-OHSD [73—75].
Evidence to support a role for 1 1J3-OHSD in the syndrome of
apparent mineralocorticoid excess has also been provided by
investigations of licorice-induced pseudoaldosteronism [76].
Licorice has been used for centuries as both a food additive and
a medicinal [77]. The administration of licorice (or the active
agent glycyrrhetinic acid, GA) has long been recognized to
produce spironolactone-responsive Na retention, hypokaleniia
and hypertension characterized by suppression of the renin-
aldosterone system [78, 79]. These effects are not observed in
patients with Addison's disease [80] or in the adrenalectomized
animal [81], but can be reproduced when glucocorticoids are
replaced. Furthermore, the administration of the medical form
of licorice (carbenoxolone) causes corticosterone and cortisol
to be kaliuretic and antinatriuretic in the adrenalectomized rat
[82]. Also, GA administration to normal humans resulted in
increased excretion of free cortisol and a decrease in the
THE:THF ratio similar to that seen in patients with AME [83].
An inhibitory effect of GA on rat kidney 1 1/3-OH SD has been
demonstrated both in vivo and in vitro [84]. However, the
mineralocorticoid actions of licorice may be complex in origin.
For instance, GA has been shown to decrease 5/3-reductase,
and thereby increase the production of the mineralocorticoid
5a-dihydroaldosterone in rat liver preparations [85]. Similar
effects are observed with carbenoxolone which is frequently
associated with the induction of hypertension and hypokalemia
when used for the treatment of peptic ulcer disease [861.
Indeed, the administration of this agent enhances Na retention
by deoxycorticosterone, a steroid which is not a substrate for
ll/3-OHSD, perhaps explained by the inhibition of 5/3-reductase
[87]. The recent descriptions of a variant (Type 2) form of AME
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characterized by decreased cortisol clearance without defective
cortisol oxidation or increased 5a reduction [88—90] suggest that
alternative mechanisms for cortisol-mediated Na retention may
exist. In contrast to patients with the Type 1 AME, subjects
identified with the Type 2 variant responded less well to
spironolactone and better to dexamethasone suppression of
cortisol. Ulick and coworkers suggested that the common
denominator in both types is defective A-ring reduction [91]. In
neither type of AME has the genetic defect(s) been identified.
Strong evidence for a central role for 1 1/3-OHSD deficiency
(congential or acquired) in the apparent mineralocorticoid ac-
tion of coi-tisol has stimulated intensive work on characteriza-
tion and localization of the enzyme. As noted above, 1 1/3-
OHSD is an oxido-reductase which catalyzes the oxidation of
cortisol to cortisone (11/3-dehydogenase) in the presence of
NADP and the NADPH-dependent reduction of cortisone to
cortisol (1 1-oxo-reductase). Preferential activity of either the
dehydrogenase or the reductase (but not both) in the tissues
examined suggested to many that the two were separate gene
products dependent upon the NADP/NADPH ratio present
[92]. However, purification and expression of an 1 1/3-dehydro-
genase eDNA has demonstrated that the two activities are
contained within a single 34,000 molecular wt glycoprotein
which may be under differential regulation [4]. Based upon
Western blot analysis, ll/3-OHSD immunoreactivity is readily
demonstrated in liver, kidney, testis, gut, parotid, lung, pla-
centa, thyroid, brain and vascular smooth muscle [93]. With
respect to the kidney, early studies, using antibodies directed
against liver enzyme preparations, revealed a paradoxical stain-
ing for 1 l/3-OHSD in the proximal tubule and Type I receptor
immunoreactivity in the distal tubule [75]. More recently,
however, colocalization of the enzyme and the Type I receptor
has been reported in the cortical collecting duct using assays for
1 1f3-dehydrogenase catalytic activity [94, 95], and utilizing in
situ hybridization [96]. Northern blot analysis suggests that a
distinct isoform of the enzyme exists in the distal tubule which
is not recognized by antibodies to the hepatic form, thus
explaining the failure of earlier studies to demonstrate 11/3-
OHSD immunoreactivity despite clear bioactivity [97]. A direct
test of the hypothesis of the role of 1 113-dehydrogenation
regulation in alteration of occupancy and of activation of the
Type I receptor by glucocorticoids has not been done. In other
words, correlation of change in 11 /3-OH SD activity with change
in receptor occupancy and proportionate change in active Na
transport has yet to be reported. However, Naray-Fejes-Toth et
al have provided evidence in primary culture of cortical collect-
ing duct of the rabbit that intracellular levels of corticosterone
are probably nil, and that licorice inhibits 1 l/3-OHSD with an
apparent increase in intracellular corticosterone 194].
The forms of 1 lf3-OHSD deficiency described above are rare,
but a number of common clinical conditions associated with
Na retention and blood pressure elevation exhibit alterations
in cortisol:cortisone interconversion. Edwards and coworkers
have presented evidence that ACTH may decrease 11/3-OHSD,
and thus amplify its increase in cortisol secretion on circulating
plasma cortisol [98]. Indeed, they find decreased urinary THE:
THF ratio in the syndrome of ectopic ACTH, which is associ-
ated with very high circulating ACTH concentration and usu-
ally shows evidence of a substantial degree of mineralocorticoid
excess. Hyperthyroidism is associated with increased 11/3-
dehydrogenase compared to 1 1-oxo-reductase activity while
both rates are decreased in patients with hypothyroidism in
association with a decreased THE:THF ratio [99]. In addition,
insulin and human serum have been shown to decrease 11/3-
OHSD activity [100]. However, sensitivity to spironolactone is
not characteristic of hypertension associated with hyperinsulin-
ism. Similarly, the syndrome of "pseudohyperaldosteronism"
(enhanced Na reabsorption, hypokalemia and hypertension
with suppressed renin and aldosterone secretion) first described
by Liddle [101] does not respond to spironolactone. To our
knowledge, THE:THF ratios have not been performed in these
patients. Given the increasing association of hyperinsulinemia
(and diabetes mellitus) to hypertension, a link between dimin-
ished 1 1/3-dehydrogenase activity and hypertension will likely
be a continuously fruitful area of investigation. Indeed, de-
creased urinary THE:THF ratios have been reported in 15% of
low renin essential hypertensives and 5% of normal renin
hypertensive subjects [102]. It is also possible that diminished
1lJ3-OHSD activity might enhance 6/3-OHase activity by en-
hancing steroid induction of this enzyme.
The possibility of a third corticosteroid receptor
The idea that 6/3-hydroxylation of steroids in kidney may play
a physiologic or pathophysiologic role stems from our studies of
A6 cells, a continuous line in culture derived from kidney of
Xenopus laevis. Examination of A6 cell steroid receptors by in
situ nuclear binding and by cytosolic binding of both aldoste-
rone and corticosterone confirmed the presence of two sites
exhibiting properties typical of mammalian cytosolic Type I and
Type II receptors [103, 104]. Subsequently, we demonstrated in
epithelia incubated with radiolabeled corticosterone that 6/3-
OH-B, the major metabolite of corticosterone in A6 cells [13],
occupied a third, lower affinity set of nuclear binding sites
which we refer to as Type IV receptors [14]. These findings in
A6 cells prompted us to formulate a new hypothesis for
corticosteroid action based on the idea that receptors analogous
to Type IV receptors may be conserved and manifest some-
where in mammalian kidney, just as Type I and Type II are
conserved.
Figure 3 shows this hypothesis in which the Type I receptor,
shielded from the action of glucocorticoids by 1 l/3-OHSD,
regulates urinary Na excretion when activated by aldosterone
but not by glucocorticoids. We do not show Type II receptor
mediation of glucocorticoid-induced Na retention since we
found no evidence of this in our studies of coadministration of
RU486 and cortisol [521. Also, we think the evidence for the
occurrence of this phenomenon in vivo is insufficient. The Type
IV receptor exhibited half-maximal occupancy by 6/3-OH-B
(derived in the effector cell from corticosterone) at a corticos-
terone extracellular concentration of 3 x 107M in A6 cells.
Thus, we consider these sites of lower affinity not to be
occupied by steroids or their 6/3-OH derivatives at physiologic
concentration of glucocorticoids (circulating free concentration
of cortisol in humans and corticosterone in rat of approximately
108M) [14]. However, two situations are envisioned in which
intracellular concentrations of steroids would be sufficiently
high to occupy and activate the Type IV receptor, should it
exist in mammals: (1) when free circulating glucocorticoid
concentrations reach 107M or above as in stress, or (2) when
target cell steroid 6/3-hydroxylase in enhanced [14]. We have
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Fig. 3. Hypothetical scheme of receptors mediating glucocorticoid
action on urinary Na excretion in mammalian kidney, that is, miner-
alocorticoid (Type 1), glucocorticoid (Type II) and low affinity (Type IV)
receptor. This hypothesis is based on our studies in A6 epithelia [14].
We envision that the Type IV mechanism would be present only in a
discrete portion of the kidney as is steroid 6/3-hydroxylase, such as the
collecting tubule [12], and would be activated only in stress or when
6/3-hydroxylase activity is enhanced. Abbreviations are: 1 1/3-hydroxy-
steroid dehydrogenase, 1 1J3-OHSD; glucocorticoid, G; extracellular,
EC; intracellular, IC; glucocorticoid 6f3-hydroxylase, G-6/3-OHase.
previously discussed our evidence that stress level cortisol
induced urinary Na retention and BP increase may be medi-
ated by a third receptor. Next we consider the second possibil-
ity, that enhanced glucocorticoid 6/3-hydroxylation could be
pathophysiologically important.
Glucocorticoid 6j3-hydroxylation in hypertensive states
Increased urinary excretion of 6/3-OH-F, relative to parame-
ters of cortisol secretion, has been reported in several syn-
dromes associated with hypertension, that is, Cushing's syn-
drome [105], hypothyroidism [1061, estrogen administration
[105], and the third trimester of pregnancy with especially high
values in toxemia [1071. Thus, increased cortisol 6/3-OHase
activity could either be a primary etiologic factor, serve as a
risk factor, or contribute to stress induced enhancement of
essential hypertension. The increase could be on a genetic basis
(enzyme polymorphism) or as a result of environmental expo-
sure (drugs and xenobiotics induce cortisol 6/3-hydroxylation in
humans). The major 6$-hydroxylases are family 3A microsomal
cytochromes P-450 [108, 109]. Increased family 3A enzyme has
been demonstrated in SHR liver compared to normotensive
control WKY rats [110, 111]. However, the BP elevation in
SHR is renal cytochrome P-450 dependent [112, 113]. In keep-
ing with these latter finding we have recently shown that renal
glucocorticoid 6/3-hydroxylation catalyzed by family 3A micro-
somal cytochromes P-450 is markedly increased in SHR (six- to
sevenfold), whereas barely detectable activity is found in the
control WKY rat (S. Ghosh, W.M. Grogan, C.O. Watlington,
unpublished observations). Troleandomycin (TAO), a putative
selective inhibitor of family 3A P-450's, inhibited in vivo
6f3-hydroxylation and dramatically lowered BP [1141. Thus, we
postulate that excessive 6f3-OH-corticosterone production from
corticosterone results from increased family 3A P-450 catalytic
activity at some nephron site (immunohistochemistry reveals
family 3A protein in the renal collecting tubule only in SHR and
WKY rats; Naray-Fejes-Toth, unpublished observations) and
leads to increased transcellular active Na transport. The result
is a modest but chronic increase in Na reabsorption at this
site, that is, a renal defect in Na1 excretion, as postulated for
essential hypertension in humans and in SHR, which subse-
quently leads to systemic hypertension. Indeed, 6/3-OH-corti-
costerone does produce a modest Na retention when admin-
istered to rats [15].
This hypothesis could explain modification of the hyperten-
sion by alteration of Na intake [115, 116] and the adrenal
influence [117—119], renal dependence [120, 121] and renal
P-450 dependence [113] of BP elevation in SHR. The renal Na
retentive mechanism hypothesized may be necessary, but not
sufficient, to produce a component of BP elevation in SHR.
Thus, this hypothesis does not preclude a pathogenetic role for
steroid 6/3-hydroxylation in sites other than the kidney, such as
brain and vascular smooth muscle. Similarly, an interaction
with other intermediate phenotypes involving the brain, vascu-
lature or other systems may be needed for expression of an
effect of enhanced 6/3-hydroxylation on BP. Our findings are at
least consistent with a role for the increased activity of family
3A cytochromes P-450 in the development of hypertension in
the SHR, but much more work needs to be done to substantiate
this possibility. A further assessment of enhanced glucocorti-
coid 6/3-hydroxylation as an intermediate phenotype or risk
factor for hypertension in humans should be made. Indeed, we
have preliminary evidence that a subset of Black essential
hypertensives exhibits excessive 6f3-hydroxylation (J. Wright,
W.M. Grogan, H. Estep, C. Watlington, unpublished observa-
tions).
Glucocorticoid control of receptor expression
In addition to the concept of glucocorticoid occupancy of
Type I receptors in tissues with diminished 1 lj3-OHSD activity,
glucocorticoids may also regulate Type I receptor expression
negatively as well as positively. For example, the findings that
the concentrations of F expected in marked stress [52] produce
Na retention not mediated by the Type I receptor are not
inconsistent with the evidence for Type I receptor-mediated
effects by F in the syndrome of apparent mineralocorticoid
excess. The latter conditions are associated with much lower
plasma F concentrations. Very high concentrations of F may
suppress the expression of the Type I receptor in terms of real
Na retention. This could explain the absence of Type I
receptor-mediated Na retention in subjects given high dose F
(240 mg/day) or high dose ACTH despite evidence for a very
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modest mineralocorticoid receptor activation at a lower dosage
of F (120 mg/day) [521 and in the syndrome of apparent
mineralocorticoid excess. Indeed, Kenyon and coworkers [122]
have confirmed earlier reports that high dose corticosterone
reduces the Na retention produced by aldosterone in the rat,
consistent with such a Type I receptor inhibitory mechanism of
glucocorticoids. The inhibition of Type I receptor-mediated
Na retention by glucocorticoids could also be due to an
opposing and concomitant natriuretic effect mediated by the
Type II receptor [20]. Alternatively, glucocorticoids could exert
effects on Type I receptor interaction with the nucleus and/or
on subsequent transcriptional, translational, or posttransla-
tional events. Although there have been no reports that clarify
the mechanism of this inhibition, recent studies suggest that
glucocorticoid-mediated inhibition of type I receptor activation
is a direct epithelial effect rather than an indirect effect (for
example, through hemodynamic changes) [123, 124]. It is also
clear that Type I receptor activation, which is extrarenal, can
occur concomitantly with renal actions of cortisol that are not
mediated by the Type I receptor. As noted above (Table 3),
spironolactone inhibits high dose cortisol induced decrease in
serum K but does not inhibit the concomitant antinatriuresis
[53].
Expression of Type II mediated active Na transport stimu-
lation may also be regulated. Glucocorticoids were shown to
stimulate active Na transport in toad bladder in the early
1960's [125]. More recently, correlations of aldosterone and
corticosterone stimulation Of active Na transport and occu-
pancy of Type II receptors were found in amphibian epithelia,
both A6 cells [103] and toad bladder [126]. Aniko Naray
Fejes-Toth has recently shown evidence of Type II receptor-
mediated active Na transport stimulation in primary cultures
of cortical collecting duct of rabbit [127], and Stokes et al have
provided similar results in primary cultures of the medullary
collecting duct of rat [128]. However, glucocorticoids do not
usually seem to cause urinary Na retention by Type II
receptor mediation in vivo [52, 129], but do regulate other renal
functions such as ammoniagenesis and transient kaliuresis
(Table 2). Funder et al have reported evidence for mineralocor-
ticoid-like glucocorticoid-induced alteration in urinary electro-
lyte excretion in human subjects who lack Type I receptors and
in rats administered the highly specific glucocorticoid, RU-
28362 [129]. They found a decrease in urinary Na/K ratios in
these two conditions and attributed the change in urinary
electrolytes to Type II receptor-mediated events. However,
changes in the Na/K ratio may be misleading, since Type II
receptor mediated kaliuresis alone, a well established glucocor-
ticoid effect in humans and rat [52, 129], could lower the ratio in
the absence of urinary Na retention. In addition, they did not
demonstrate, in either situation, that the Type II receptor
antagonist RU486 inhibited the Na retention attributed to
Type II receptor. Thus, the renal tubule is capable of Type II
receptor mediated Na transport stimulation in vitro, but the
mechanism seems suppressed in vivo.
Summary
(1) Decreased I 1/3-OHSD activity permits binding of cortisol
to the Type I (mineralocorticoid) receptor in humans, thereby
producing spironolactone-inhibitable Na retention, hypokale-
mia and hypertension, the syndrome of apparent mineralocor-
ticoid excess (AME).
(2) Blockade of either the Type I receptor with spironolac-
tone or the Type II (glucocorticoid) receptor with RU-486 does
not consistently abolish the effects of stress level cortisol on
Na retention and hypertension in acute studies in normal
humans, suggesting the existence of an additional glucocorti-
coid receptor.
(3) Enhanced glucocorticoid 6/3-hydroxylation could play an
etiologic role in certain hypertensive syndromes.
(4) Both decreased 1 1/3-OHSD and increased 6J3-OHase are
candidates as intermediate phenotypes for the remote pheno-
type essential hypertension.
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